{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:55Z","timestamp":1792723135775,"version":"4.5.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01662-9","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:32:10Z","timestamp":1792675930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Centered Value Elements in the Economic Evaluation of Chronic Obstructive Pulmonary Disease (COPD): A Targeted Review of Cost-Effectiveness Analyses"],"prefix":"10.1007","author":[{"given":"Nabin","family":"Poudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Slejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"2","key":"1662_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jval.2017.12.012","volume":"21","author":"PJ Neumann","year":"2018","unstructured":"Neumann PJ, Willke RJ, Garrison LP Jr. A health economics approach to US value assessment frameworks: introduction: an ISPOR Special Task Force report [1]. Value Health. 2018;21(2):119\u201323.","journal-title":"Value Health"},{"issue":"1","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-6296(96)00506-1","volume":"16","author":"AM Garber","year":"1997","unstructured":"Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16(1):1\u201331.","journal-title":"J Health Econ"},{"issue":"5","key":"1662_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jval.2019.01.010","volume":"22","author":"CE Phelps","year":"2019","unstructured":"Phelps CE, Madhavan G. Valuing health: evolution, revolution, resistance, and reform. Value Health. 2019;22(5):505\u201310.","journal-title":"Value Health."},{"issue":"10","key":"1662_CR4","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jval.2025.06.014","volume":"28","author":"JF Slejko","year":"2025","unstructured":"Slejko JF, Lavelle TA, Vandigo J, Escontr\u00edas OA, Schoch SC, Oehrlein EM. Achieving patient-centered value\/health technology assessment: recommendations from a multistakeholder eDelphi Panel. Value Health. 2025;28(10):1472\u201380.","journal-title":"Value Health"},{"key":"1662_CR5","unstructured":"Mattingly TJ, Slejko JF, Oehrlein EM, Perfetto EM. Nudging health economists: a process for systematic identification of patient-entered outcomes for inclusion in value assessment. Value & Outcomes Spotlight. 2021;7(Suppl 2):S11\u2013S14."},{"issue":"5","key":"1662_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jval.2019.02.003","volume":"22","author":"JF Slejko","year":"2019","unstructured":"Slejko JF, Mattingly TJ II, Mullins CD, Perfetto EM, dosReis S. Future of patients in healthcare evaluation: the patient-informed reference case. Value Health. 2019;22(5):545\u20138.","journal-title":"Value Health."},{"issue":"6","key":"1662_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40273-021-01036-3","volume":"39","author":"RZ Xie","year":"2021","unstructured":"Xie RZ, Malik ED, Linthicum MT, Bright JL. Putting stakeholder engagement at the center of health economic modeling for health technology assessment in the United States. Pharmacoeconomics. 2021;39(6):631\u20138.","journal-title":"Pharmacoeconomics"},{"key":"1662_CR8","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232100012X","volume":"37","author":"S Staniszewska","year":"2021","unstructured":"Staniszewska S, S\u00f6derholm Werk\u00f6 S. Mind the evidence gap: the use of patient-based evidence to create \u201ccomplete HTA\u201d in the twenty-first century. Int J Technol Assess Health Care. 2021;37:e46.","journal-title":"Int J Technol Assess Health Care"},{"key":"1662_CR9","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000064","volume":"37","author":"MP Gagnon","year":"2021","unstructured":"Gagnon MP, Tantchou Dipankui M, Poder TG, Payne-Gagnon J, Mbemba G, Beretta V. Patient and public involvement in health technology assessment: update of a systematic review of international experiences. Int J Technol Assess Health Care. 2021;37:e36.","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"1662_CR10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jval.2019.04.1930","volume":"22","author":"SPI Huls","year":"2019","unstructured":"Huls SPI, Whichello CL, van Exel J, Uyl-de Groot CA, de Bekker-Grob EW. What is next for patient preferences in health technology assessment? A systematic review of the challenges. Value Health. 2019;22(11):1318\u201328.","journal-title":"Value Health"},{"issue":"4","key":"1662_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jval.2017.11.013","volume":"21","author":"EM Perfetto","year":"2018","unstructured":"Perfetto EM, Harris J, Mullins CD, dosReis S. Emerging good practices for transforming value assessment: patients\u2019 voices, patients\u2019 values. Value Health. 2018;21(4):386\u201393.","journal-title":"Value Health"},{"issue":"6","key":"1662_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40271-018-0325-5","volume":"11","author":"KM Facey","year":"2018","unstructured":"Facey KM, Bedlington N, Berglas S, Bertelsen N, Single ANV, Thomas V. Putting patients at the centre of healthcare: progress and challenges for health technology assessments. Patient. 2018;11(6):581\u20139.","journal-title":"Patient"},{"issue":"8","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10198-020-01182-z","volume":"21","author":"M Drummond","year":"2020","unstructured":"Drummond M, Torbica A, Tarricone R. Should health technology assessment be more patient centric? If so, how? Eur J Health Econ. 2020;21(8):1117\u201320.","journal-title":"Eur J Health Econ"},{"key":"1662_CR14","doi-asserted-by":"publisher","unstructured":"Balch A, Lakdawalla DN. The case for patient-centered assessment of value. Health Affairs Forefront. May 8, 2017. https:\/\/doi.org\/10.1377\/forefront.20170508.059180.","DOI":"10.1377\/forefront.20170508.059180"},{"issue":"19","key":"1662_CR15","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.2016.4637","volume":"315","author":"E Basch","year":"2016","unstructured":"Basch E. Toward a patient-centered value framework in oncology. JAMA. 2016;315(19):2073\u20134.","journal-title":"JAMA"},{"issue":"7","key":"1662_CR16","first-page":"936","volume":"27","author":"A Inotai","year":"2021","unstructured":"Inotai A, Jakab I, Brixner D, Campbell JD, Hawkins N, Kristensen LE, et al. Proposal for capturing patient experience through extended value frameworks of health technologies. J Manag Care Spec Pharm. 2021;27(7):936\u201347.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"1662_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40271-021-00495-2","volume":"14","author":"JF Slejko","year":"2021","unstructured":"Slejko JF, Hong YD, Sullivan JL, Reed RM, dosReis S. Prioritization and refinement of patient-informed value elements as attributes for chronic obstructive pulmonary disease treatment preferences. Patient-Patient-Centered Outcomes Res. 2021;14(5):569\u201379.","journal-title":"Patient-Patient-Centered Outcomes Res"},{"issue":"1","key":"1662_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1017\/S0266462307051549","volume":"23","author":"JFP Bridges","year":"2007","unstructured":"Bridges JFP, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care. 2007;23(1):30\u20135.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"1662_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40271-018-0305-9","volume":"11","author":"DJ Mott","year":"2018","unstructured":"Mott DJ. Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? Patient. 2018;11(3):249\u201352.","journal-title":"Patient"},{"issue":"2","key":"1662_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care: a health economics approach: an ISPOR Special Task Force report [3]. Value Health. 2018;21(2):131\u20139.","journal-title":"Value Health."},{"issue":"1","key":"1662_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jval.2023.09.2910","volume":"27","author":"RB McQueen","year":"2024","unstructured":"McQueen RB, Inotai A, Zemplenyi A, Mendola N, N\u00e9meth B, Kalo Z. Multistakeholder perceptions of additional value elements for United States value assessment of health interventions. Value Health. 2024;27(1):15\u201325.","journal-title":"Value Health"},{"issue":"2","key":"1662_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jval.2016.12.005","volume":"20","author":"LP Garrison Jr","year":"2017","unstructured":"Garrison LP Jr, Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health. 2017;20(2):213\u20136.","journal-title":"Value Health."},{"issue":"8","key":"1662_CR23","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jval.2022.01.025","volume":"25","author":"S Ma","year":"2022","unstructured":"Ma S, Olchanski N, Cohen JT, Ollendorf DA, Neumann PJ, Kim DD. The impact of broader value elements on cost-effectiveness analysis: two case studies. Value Health. 2022;25(8):1336\u201343.","journal-title":"Value Health."},{"issue":"1","key":"1662_CR24","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000490","volume":"37","author":"K Marsh","year":"2021","unstructured":"Marsh K, de Bekker-Grob E, Cook N, Collacott H, Danyliv A. How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations. Int J Technol Assess Health Care. 2021;37(1):e75.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"1662_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40271-024-00676-9","volume":"17","author":"K Marsh","year":"2024","unstructured":"Marsh K, Collacott H, Thomson J, Mauer J, Watt S, Shah K, et al. Using patient preferences in health technology assessment: evaluating quality-adjusted survival equivalents (QASE) for the quantification of non-health Benefits. Patient. 2024;17(3):229\u201337.","journal-title":"Patient"},{"issue":"10","key":"1662_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","volume":"38","author":"DD Kim","year":"2020","unstructured":"Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974\u20132018. Pharmacoeconomics. 2020;38(10):1135\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1662_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40271-017-0272-6","volume":"10","author":"B Levitan","year":"2017","unstructured":"Levitan B, Hauber AB, Damiano MG, Jaffe R, Christopher S. The ball is in your court: agenda for research to advance the science of patient preferences in the regulatory review of medical devices in the United States. Patient-Patient-Centered Outcomes Res. 2017;10(5):531\u20136.","journal-title":"Patient-Patient-Centered Outcomes Res"},{"issue":"4","key":"1662_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2217\/cer-2020-0190","volume":"10","author":"S Hendriks","year":"2021","unstructured":"Hendriks S, Pearson SD. Assessing potential cures: are there distinctive elements of value beyond health gain? J Comp Eff Res. 2021;10(4):255\u201365.","journal-title":"J Comp Eff Res."},{"key":"1662_CR29","unstructured":"McQueen RB, Wailoo A, Tsuchiya A, Cipriano LE, Guertin JR, Schmidler GDS, et al. Defining appropriate benefits for economic evaluation of health care technologies. Denver, CO: Health Economics Methods Advisory (HEMA); March11, 2026."},{"issue":"6","key":"1662_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/medethics-2020-106503","volume":"48","author":"JA Michaels","year":"2022","unstructured":"Michaels JA. Value assessment frameworks: who is valuing the care in healthcare? J Med Ethics. 2022;48(6):419\u201326.","journal-title":"J Med Ethics"},{"issue":"10","key":"1662_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"9","key":"1662_CR32","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jval.2022.03.006","volume":"25","author":"T Peasgood","year":"2022","unstructured":"Peasgood T, Mukuria C, Rowen D, Tsuchiya A, Wailoo A. Should we consider including a value for \u201chope\u201d as an additional benefit within health technology assessment? Value Health. 2022;25(9):1619\u201323.","journal-title":"Value Health."},{"issue":"5","key":"1662_CR33","first-page":"650","volume":"27","author":"J Shafrin","year":"2021","unstructured":"Shafrin J, Dennen S, Pednekar P, Birch K, Bhor M, Kanter J, et al. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports. J Manag Care Spec Pharm. 2021;27(5):650\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1662_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40273-018-0729-z","volume":"37","author":"C McCabe","year":"2019","unstructured":"McCabe C. Expanding the scope of costs and benefits for economic evaluations in health: some words of caution. Pharmacoeconomics. 2019;37(4):457\u201360.","journal-title":"Pharmacoeconomics"},{"key":"1662_CR35","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report. Global Initiative for Chronic Obstructive Lung Disease; 2026. Available from: https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/. [Accessed 10 Jul 2026]"},{"key":"1662_CR36","unstructured":"Center for the Evaluation of Value and Risk in Health. CEA Registry. 2023. Available from: https:\/\/cevr.tuftsmedicalcenter.org\/databases\/cea-registry. [Accessed 28 Aug 2026]."},{"key":"1662_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1662_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2147\/COPD.S173057","volume":"14","author":"J Bourbeau","year":"2019","unstructured":"Bourbeau J, Granados D, Roze S, Durand-Zaleski I, Casan P, K\u00f6hler D, et al. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program. Int J Chron Obstruct Pulmon Dis. 2019;14:645\u201357.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"1662_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/resp.13667","volume":"25","author":"AT Burge","year":"2020","unstructured":"Burge AT, Holland AE, McDonald CF, Abramson MJ, Hill CJ, Lee AL, et al. Home-based pulmonary rehabilitation for COPD using minimal resources: an economic analysis. Respirology. 2020;25(2):183\u201390.","journal-title":"Respirology"},{"issue":"7","key":"1662_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40261-018-0646-0","volume":"38","author":"M Capel","year":"2018","unstructured":"Capel M, Mareque M, \u00c1lvarez CJ, Lindner L, Oyag\u00fcez I. Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig. 2018;38(7):611\u201320.","journal-title":"Clin Drug Investig"},{"key":"1662_CR41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/COPD.S159103","volume":"13","author":"MC Chan","year":"2018","unstructured":"Chan MC, Tan EC, Yang MC. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1079\u201388.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1662_CR42","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1080\/13696998.2022.2096892","volume":"25","author":"L Chen","year":"2022","unstructured":"Chen L, Chen X, Zhi C, Li X, Hu Y. Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis. J Med Econ. 2022;25(1):966\u201373.","journal-title":"J Med Econ"},{"key":"1662_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.rmed.2018.10.024","volume":"145","author":"M Driessen","year":"2018","unstructured":"Driessen M, Shah D, Risebrough N, Baker T, Naya I, Briggs A, et al. Cost-effectiveness of umeclidinium as add-on to ICS\/LABA therapy in COPD: a UK perspective. Respir Med. 2018;145:130\u20137.","journal-title":"Respir Med"},{"issue":"1","key":"1662_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0916-7","volume":"19","author":"MT Driessen","year":"2018","unstructured":"Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, et al. Cost-effectiveness analysis of umeclidinium bromide\/vilanterol 62.5\/25 mcg versus tiotropium\/olodaterol 5\/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish national healthcare system perspective. Respir Res. 2018;19(1):224.","journal-title":"Respir Res"},{"issue":"8","key":"1662_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/thoraxjnl-2017-211197","volume":"73","author":"C Echevarria","year":"2018","unstructured":"Echevarria C, Gray J, Hartley T, Steer J, Miller J, Simpson AJ, et al. Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation. Thorax. 2018;73(8):713\u201322.","journal-title":"Thorax"},{"issue":"1","key":"1662_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/1357633X211037207","volume":"30","author":"C Esteban","year":"2024","unstructured":"Esteban C, Ant\u00f3n A, Moraza J, Iriberri M, Larrauri M, Mar J, et al. Cost-effectiveness of a telemonitoring program (telEPOC program) in frequently admitted chronic obstructive pulmonary disease patients. J Telemed Telecare. 2024;30(1):156\u201364.","journal-title":"J Telemed Telecare"},{"issue":"1","key":"1662_CR47","doi-asserted-by":"publisher","first-page":"00480","DOI":"10.1183\/23120541.00480-2020","volume":"7","author":"E Fenwick","year":"2021","unstructured":"Fenwick E, Martin A, Schroeder M, Mealing SJ, Solanke O, Risebrough N, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7(1):00480\u20132020.","journal-title":"ERJ Open Res."},{"key":"1662_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/COPD.S276476","volume":"16","author":"S Gong","year":"2021","unstructured":"Gong S, Hu H, Zhao K, Yang T. Cost-effectiveness of dual bronchodilator indacaterol\/glycopyrronium for COPD treatment in China. Int J Chron Obstruct Pulmon Dis. 2021;16:433\u201341.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR49","first-page":"2878648","volume":"2022","author":"Y Gong","year":"2022","unstructured":"Gong Y, Lin C, Jin Y, Chen R. The efficacy and cost-effectiveness of umeclidinium\/vilanterol versus tiotropium in symptomatic patients with chronic obstructive pulmonary disease. Can Respir J. 2022;2022:2878648.","journal-title":"Can Respir J"},{"issue":"10","key":"1662_CR50","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1136\/thoraxjnl-2021-217463","volume":"77","author":"J Hall","year":"2022","unstructured":"Hall J, Turner AM, Dretzke J, Moore D, Jowett S. Cost-effectiveness of domiciliary non-invasive ventilation in patients with chronic obstructive pulmonary disease. Thorax. 2022;77(10):976\u201386.","journal-title":"Thorax"},{"key":"1662_CR51","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/COPD.S370577","volume":"17","author":"DMG Halpin","year":"2022","unstructured":"Halpin DMG, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, et al. Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID Trial. Int J Chron Obstruct Pulmon Dis. 2022;17:2745\u201355.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/COPD.S191031","volume":"14","author":"M Hoogendoorn","year":"2019","unstructured":"Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, et al. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. Int J Chron Obstruct Pulmon Dis. 2019;14:447\u201356.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"1662_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049675","volume":"11","author":"M Hoogendoorn","year":"2021","unstructured":"Hoogendoorn M, Corro Ramos I, Soulard S, Cook J, Soini E, Paulsson E, et al. Cost-effectiveness of the fixed-dose combination tiotropium\/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting \u03b22-agonist\/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. BMJ Open. 2021;11(8):e049675.","journal-title":"BMJ Open"},{"key":"1662_CR54","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/COPD.S400707","volume":"18","author":"R Kendall","year":"2023","unstructured":"Kendall R, Martin AA, Shah D, Shukla S, Compton C, Ismaila AS. Cost-effectiveness of single-inhaler triple therapy (FF\/UMEC\/VI) versus tiotropium monotherapy in patients with symptomatic moderate-to-very severe COPD in the UK. Int J Chron Obstruct Pulmon Dis. 2023;18:1815\u201325.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR55","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.2147\/COPD.S167730","volume":"13","author":"C Kiff","year":"2018","unstructured":"Kiff C, Ruiz S, Varol N, Gibson D, Davies A, Purkayastha D. Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK. Int J Chron Obstruct Pulmon Dis. 2018;13:2707\u201320.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR56","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2147\/COPD.S247156","volume":"15","author":"B Lakhotia","year":"2020","unstructured":"Lakhotia B, Mahon R, Gutzwiller FS, Danyliv A, Nikolaev I, Thokala P. Modelling the cost-effectiveness of indacaterol\/glycopyrronium versus salmeterol\/fluticasone using a novel Markov exacerbation-based approach. Int J Chron Obstruct Pulmon Dis. 2020;15:787\u201397.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR57","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2147\/COPD.S350218","volume":"17","author":"Y Lan","year":"2022","unstructured":"Lan Y, Yang N, Wang Y, Yang Y, Xu M, He Q. Cost-effectiveness of umeclidinium\/vilanterol versus salmeterol\/fluticasone in elderly patients with chronic obstructive pulmonary diseases in China. Int J Chron Obstruct Pulmon Dis. 2022;17:609\u201319.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR58","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/COPD.S425409","volume":"18","author":"Y Lan","year":"2023","unstructured":"Lan Y, Yang N, Wang Y, Yang Y, Xu M, He Q. Cost-effectiveness analysis of fixed-dose tiotropium\/olodaterol versus tiotropium for COPD patients in China. Int J Chron Obstruct Pulmon Dis. 2023;18:2093\u2013103.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"1662_CR59","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/jgs.15834","volume":"67","author":"T Maricoto","year":"2019","unstructured":"Maricoto T, Marques-Gomes J, Correia-de-Sousa J, Taborda-Barata L. Inhaler review in older dults with Asathma or COPD: a cost-effectiveness study and a perspective in Portugal. J Am Geriatr Soc. 2019;67(7):1430\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"1662_CR60","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2147\/COPD.S253567","volume":"15","author":"M Miravitlles","year":"2020","unstructured":"Miravitlles M, Mar\u00edn A, Huerta A, Carcedo D, Villacampa A, Puig-Junoy J. Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1643\u201354.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"1662_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14737167.2019.1536550","volume":"19","author":"F Moayeri","year":"2019","unstructured":"Moayeri F, David D, Ya-Seng H, Doyle C. Cost-utility analysis of telephone-based cognitive behavior therapy in chronic obstructive pulmonary disease (COPD) patients with anxiety and depression comorbidities: an application for willingness to accept concept. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):331\u201340.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"1662_CR62","doi-asserted-by":"publisher","first-page":"e2218189","DOI":"10.1001\/jamanetworkopen.2022.18189","volume":"5","author":"CL Mosher","year":"2022","unstructured":"Mosher CL, Nanna MG, Jawitz OK, Raman V, Farrow NE, Aleem S, et al. Cost-effectiveness of pulmonary rehabilitation among US adults with chronic obstructive pulmonary disease. JAMA Netw Open. 2022;5(6):e2218189.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1662_CR63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/thorax-2022-219653","volume":"78","author":"PB Murphy","year":"2023","unstructured":"Murphy PB, Brueggenjuergen B, Reinhold T, Gu Q, Fusfeld L, Criner G, et al. Cost-effectiveness of home non-invasive ventilation in patients with persistent hypercapnia after an acute exacerbation of COPD in the UK. Thorax. 2023;78(5):523\u20135.","journal-title":"Thorax"},{"issue":"11","key":"1662_CR64","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1089\/tmj.2020.0398","volume":"27","author":"JP Ney","year":"2021","unstructured":"Ney JP, Robinson SA, Richardson CR, Moy ML. Can technology-based physical activity programs for chronic obstructive ulmonary disease be cost-effective? Telemed J E Health. 2021;27(11):1288\u201392.","journal-title":"Telemed J E Health"},{"key":"1662_CR65","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.2147\/COPD.S366765","volume":"17","author":"VF Paly","year":"2022","unstructured":"Paly VF, Vallejo-Aparicio LA, Martin A, Izquierdo JL, Riesco JA, Soler-Catalu\u00f1a JJ, et al. Cost-effectiveness of once-daily single-inhaler COPD triple therapy in Spain: IMPACT Trial. Int J Chron Obstruct Pulmon Dis. 2022;17:3097\u2013109.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1662_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018835","volume":"8","author":"TG Poder","year":"2018","unstructured":"Poder TG, Kouakou CRC, Bouchard P-A, Tremblay V, Blais S, Maltais F, et al. Cost-effectiveness of FreeO2 in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec. BMJ Open. 2018;8(1):e018835.","journal-title":"BMJ Open"},{"key":"1662_CR67","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/COPD.S181194","volume":"14","author":"M Ramos","year":"2019","unstructured":"Ramos M, Lamotte M, Gerlier L, Svangren P, Miquel-Cases A, Haughney J. Cost-effectiveness of physical activity in the management of COPD patients in the UK. Int J Chron Obstruct Pulmon Dis. 2019;14:227\u201339.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"1662_CR68","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1089\/tmj.2023.0010","volume":"30","author":"SA Robinson","year":"2024","unstructured":"Robinson SA, Moy ML, Ney JP. Value of information analysis of a web-based self-management intervention for chronic obstructive pulmonary disease. Telemed J E Health. 2024;30(2):518\u201326.","journal-title":"Telemed J E Health"},{"issue":"1","key":"1662_CR69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12962-022-00377-w","volume":"20","author":"AD Scarffe","year":"2022","unstructured":"Scarffe AD, Licskai CJ, Ferrone M, Brand K, Thavorn K, Coyle D. Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting. Cost Eff Resour Alloc. 2022;20(1):39.","journal-title":"Cost Eff Resour Alloc."},{"key":"1662_CR70","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2147\/COPD.S240556","volume":"15","author":"M Schroeder","year":"2020","unstructured":"Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL Trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621\u201332.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1662_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12962-018-0101-3","volume":"16","author":"D Shah","year":"2018","unstructured":"Shah D, Driessen M, Risebrough N, Baker T, Naya I, Briggs A, et al. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Eff Resour Alloc. 2018;16(1):17.","journal-title":"Cost Eff Resour Alloc."},{"key":"1662_CR72","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.2147\/COPD.S331636","volume":"16","author":"S Shukla","year":"2021","unstructured":"Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, et al. Economic evaluation of umeclidinium\/vilanterol versus umeclidinium or salmeterol in symptomatic non-exacerbating patients with COPD from a UK perspective using the GALAXY model. Int J Chron Obstruct Pulmon Dis. 2021;16:3105\u201318.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR73","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.vhri.2018.09.002","volume":"16","author":"J Skoupa","year":"2018","unstructured":"Skoupa J, Kasak V, Klimes J, Valena T. Indacaterol\/glycopyrronium versus salmeterol\/fluticasone in patients with COPD: a cost-effectiveness analysis in the Czech Republic. Value Health Reg Issues. 2018;16:112\u20138.","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"1662_CR74","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jval.2017.08.001","volume":"21","author":"SS S\u00f8rensen","year":"2018","unstructured":"S\u00f8rensen SS, Jensen MB, Pedersen KM, Ehlers L. Examining the heterogeneity and cost effectiveness of a complex intervention by segmentation of patients with chronic obstructive pulmonary disease. Value Health. 2018;21(2):239\u201347.","journal-title":"Value Health"},{"key":"1662_CR75","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/CEOR.S312523","volume":"13","author":"SS S\u00f8rensen","year":"2021","unstructured":"S\u00f8rensen SS, Storgaard LH, Weinreich UM. Cost-effectiveness of domiciliary high flow nasal cannula treatment in COPD patients with chronic respiratory failure. Clinicoecon Outcomes Res. 2021;13:553\u201364.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"7","key":"1662_CR76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.11622\/smedj.2018022","volume":"59","author":"A Tee","year":"2018","unstructured":"Tee A, Chow WL, Burke C, Guruprasad B. Cost-effectiveness of indacaterol\/glycopyrronium in comparison with salmeterol\/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore. Singapore Med J. 2018;59(7):383\u20139.","journal-title":"Singapore Med J"},{"key":"1662_CR77","first-page":"9176504","volume":"2019","author":"NX Thanh","year":"2019","unstructured":"Thanh NX, Jacobs P, Suggett J, McIvor A, Kaplan A. Cost-effectiveness of the Aerobika\u00ae oscillating positive expiratory pressure device in the management of chronic obstructive pulmonary disease exacerbations in Canada. Can Respir J. 2019;2019:9176504.","journal-title":"Can Respir J"},{"issue":"4","key":"1662_CR78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.4103\/atm.atm_70_23","volume":"18","author":"ME Toubes-Navarro","year":"2023","unstructured":"Toubes-Navarro ME, Gude-Sampedro F, \u00c1lvarez-Doba\u00f1o JM, Reyes-Santias F, R\u00e1bade-Castedo C, Rodr\u00edguez-Garc\u00eda C, et al. A pulmonary rehabilitation program reduces hospitalizations in chronic obstructive pulmonary disease patients: a cost-effectiveness study. Ann Thorac Med. 2023;18(4):190\u20138.","journal-title":"Ann Thorac Med"},{"key":"1662_CR79","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/COPD.S384591","volume":"17","author":"JA Trigueros","year":"2022","unstructured":"Trigueros JA, Garin N, Baloira A, Aceituno S, Calvo A, Prades M, et al. Cost-effectiveness analysis of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate versus dual therapy in patients with chronic obstructive pulmonary disease in Spain. Int J Chron Obstruct Pulmon Dis. 2022;17:2905\u201317.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"1662_CR80","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clnu.2019.03.001","volume":"39","author":"M van Beers","year":"2020","unstructured":"van Beers M, Rutten-van M\u00f6lken M, van de Bool C, Boland M, Kremers SPJ, Franssen FME, et al. Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: the randomized controlled NUTRAIN trial. Clin Nutr. 2020;39(2):405\u201313.","journal-title":"Clin Nutr"},{"issue":"1","key":"1662_CR81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41533-018-0092-8","volume":"28","author":"JFM van Boven","year":"2018","unstructured":"van Boven JFM, Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka MC, et al. Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. NPJ Prim Care Respir Med. 2018;28(1):24.","journal-title":"NPJ Prim Care Respir Med."},{"key":"1662_CR82","doi-asserted-by":"publisher","first-page":"6478926","DOI":"10.1155\/2019\/6478926","volume":"2019","author":"XQ Yu","year":"2019","unstructured":"Yu XQ, Yang SG, Li H, Xie Y, Li JS, Zhang P. Preliminary study to evaluate three different treatments on stable chronic obstructive pulmonary disease patients based on Markov model. Evid Based Complement Alternat Med. 2019;2019:6478926.","journal-title":"Evid Based Complement Alternat Med."},{"key":"1662_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.713258","volume":"9","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Long E, Xu Q, Wang L, Jiang X, Hu M. Cost-effectiveness analysis of triple combination preparations in the treatment of moderate-to-severe chronic obstructive pulmonary disease. Front Public Health. 2021;9:713258.","journal-title":"Front Public Health"},{"issue":"1","key":"1662_CR84","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0111","volume":"15","author":"K Parsekar","year":"2026","unstructured":"Parsekar K, Pandey S, Tansey-Dwyer D, Marshall J, Rustignoli I, Pollack M, et al. Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease. J Comp Eff Res. 2026;15(1):e250111.","journal-title":"J Comp Eff Res."},{"issue":"4","key":"1662_CR85","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17476348.2025.2582249","volume":"20","author":"JA Buendia","year":"2026","unstructured":"Buendia JA, Patino DG. Is dual bronchodilation a cost-effective alternative to ICS\/LABA in COPD? A Colombian healthcare system evaluation. Expert Rev Respir Med. 2026;20(4):447\u201355.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"1662_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2025-003406","volume":"12","author":"AJ Khan","year":"2025","unstructured":"Khan AJ, Gumber A, Richardson M, Nolan CMM, Man WD, Singh S, et al. Cost-effectiveness of a self-management maintenance programme following pulmonary rehabilitation: a UK randomised controlled trial for patients with chronic obstructive pulmonary disease. BMJ Open Respir Res. 2025;12(1):e003406.","journal-title":"BMJ Open Respir Res"},{"key":"1662_CR87","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.2147\/COPD.S475748","volume":"20","author":"R Cai","year":"2025","unstructured":"Cai R, Martin AA, Ge Y, Risebrough NA, Haeussler K, Compton C, et al. Economic analysis of new single-inhaler triple therapies in patients with COPD in the UK. Int J Chron Obstruct Pulmon Dis. 2025;20:2727\u201343.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR88","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.2147\/COPD.S492524","volume":"20","author":"KM Beeh","year":"2025","unstructured":"Beeh KM, Claussen J, Shah D, Martin A, Kendall R, Dasari P, et al. Cost-effectiveness of single-inhaler versus multiple-inhaler triple therapy in COPD: a German healthcare perspective. Int J Chron Obstruct Pulmon Dis. 2025;20:2011\u201322.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107632","volume":"226","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Duan S, Zhang L, Peng F. Cost-effectiveness analysis of fluticasone furoate\/umeclidinium bromide\/vilanterol and umeclidinium bromide\/vilanterol in the management of moderate and severe COPD in China. Respir Med. 2024;226:107632.","journal-title":"Respir Med"},{"key":"1662_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107694","volume":"231","author":"NA Risebrough","year":"2024","unstructured":"Risebrough NA, Mursleen S, Ndirangu K, Shah D, Martin A, Schroeder M, et al. The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada: the IMPACT trial. Respir Med. 2024;231:107694.","journal-title":"Respir Med"},{"issue":"4","key":"1662_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301334","volume":"19","author":"JP Kuwornu","year":"2024","unstructured":"Kuwornu JP, Maldonado F, Groot G, Cooper EJ, Penz E, Sommer L, et al. An economic evaluation of chronic obstructive pulmonary disease clinical pathway in Saskatchewan, Canada: data-driven techniques to identify cost-effectiveness among patient subgroups. PLoS ONE. 2024;19(4):e0301334.","journal-title":"PLoS ONE"},{"issue":"1","key":"1662_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-024-00526-3","volume":"22","author":"YS Hwang","year":"2024","unstructured":"Hwang YS, Kim WJ, Kim TH, Park Y, Jung SM, Jo HS. Cost-utility analysis of transitional care services for older inpatients with chronic obstructive pulmonary disease (COPD) in Korea. Cost Eff Resour Alloc. 2024;22(1):19.","journal-title":"Cost Eff Resour Alloc"},{"key":"1662_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2024.108220","volume":"123","author":"CR Borge","year":"2024","unstructured":"Borge CR, Larsen MH, Osborne RH, Aas E, Kolle IT, Reinertsen R, et al. Impacts of a health literacy-informed intervention in people with chronic obstructive pulmonary disease (COPD) on hospitalization, health literacy, self-management, quality of life, and health costs: a randomized controlled trial. Patient Educ Couns. 2024;123:108220.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"1662_CR94","first-page":"4","volume":"8","author":"K Johnston","year":"2023","unstructured":"Johnston K, Shephard C, Friesen M, Azzalini C, Penz E. Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate dihydrate compared with dual therapy for the treatment of chronic obstructive pulmonary disease (COPD) in Canada. Can J Respir Crit Care Sleep Med. 2023;8(1):4\u201316.","journal-title":"Can J Respir Crit Care Sleep Med."},{"key":"1662_CR95","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/CEOR.S400739","volume":"15","author":"EJ Groessl","year":"2023","unstructured":"Groessl EJ, Tally SR, Hillery N. Cost-effectiveness of humidified high-flow therapy (HHFT) for COPD patients on long-term oxygen therapy. Clinicoecon Outcomes Res. 2023;15:239\u201350.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"1","key":"1662_CR96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40271-021-00536-w","volume":"15","author":"H Collacott","year":"2022","unstructured":"Collacott H, Zhang D, Heidenreich S, Tervonen T. A systematic and critical review of discrete choice experiments in asthma and chronic obstructive pulmonary disease. Patient. 2022;15(1):55\u201368.","journal-title":"Patient"},{"issue":"1","key":"1662_CR97","doi-asserted-by":"publisher","first-page":"1800222","DOI":"10.1183\/13993003.00222-2018","volume":"52","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Morgan RL, Alonso-Coello P, Wiercioch W, Ba\u0142a MM, Jaeschke RR, et al. A systematic review of how patients value COPD outcomes. Eur Respir J. 2018;52(1):1800222.","journal-title":"Eur Respir J"},{"key":"1662_CR98","first-page":"739","volume":"10","author":"BG Bereza","year":"2015","unstructured":"Bereza BG, Troelsgaard Nielsen A, Valgardsson S, Hemels ME, Einarson TR. Patient preferences in severe COPD and asthma: a comprehensive literature review. Int J Chron Obstruct Pulmon Dis. 2015;10:739\u201344.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR99","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/COPD.S221980","volume":"15","author":"HB Lewis","year":"2020","unstructured":"Lewis HB, Schroeder M, Gunsoy NB, Janssen EM, Llewellyn S, Doll HA, et al. Evaluating patient preferences of maintenance therapy for the treatment of chronic obstructive pulmonary disease: a discrete choice experiment in the UK, USA and Germany. Int J Chron Obstruct Pulmon Dis. 2020;15:595\u2013604.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1662_CR100","unstructured":"Lin GA, Whittington MD, Wright A, McKenna A, Richardson M, Rind DM. Ensifentrine for the Treatment of Chronic Obstructive Pulmonary Disease: Effectiveness and Value. Final Evidence Report. Boston, MA: Institute for Clinical and Economic Review; July 16, 2024. https:\/\/icer.org\/assessment\/copd-2024\/."},{"issue":"8","key":"1662_CR101","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jval.2025.02.009","volume":"28","author":"AH Seddik","year":"2025","unstructured":"Seddik AH, Paulissen J, Marapin R, Fuhler S, Johal S, Rosenlund M, et al. A comprehensive view of the methods used to measure the societal impact of healthcare interventions: a systematic review. Value Health. 2025;28(8):1288\u201399.","journal-title":"Value Health."},{"issue":"7","key":"1662_CR102","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jval.2024.03.013","volume":"27","author":"S Ghabri","year":"2024","unstructured":"Ghabri S, Dawoud D, Drummond M. Methods for including adverse events in economic evaluations: suggestions for improvement. Value Health. 2024;27(7):936\u201342.","journal-title":"Value Health."},{"issue":"5","key":"1662_CR103","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.12455","volume":"8","author":"M Zhao","year":"2025","unstructured":"Zhao M, Shao T, Yin Y, Fang H, Shao H, Tang W. Adverse event costs and cost-effectiveness analyses of anticancer drugs: a systematic review. JAMA Netw Open. 2025;8(5):e2512455.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1662_CR104","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1167","volume":"3","author":"B Patel","year":"2022","unstructured":"Patel B, Mayne P, Patri T, Vandigo J, Yin PT, Bratti K, et al. Out-of-pocket costs and prescription filling behavior of commercially insured individuals with chronic obstructive pulmonary disease. JAMA Health Forum. 2022;3(5):e221167.","journal-title":"JAMA Health Forum."},{"issue":"1","key":"1662_CR105","first-page":"4","volume":"29","author":"N Fusco","year":"2023","unstructured":"Fusco N, Sils B, Graff JS, Kistler K, Ruiz K. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: a systematic literature review. J Manag Care Spec Pharm. 2023;29(1):4\u201316.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"1662_CR106","doi-asserted-by":"publisher","first-page":"205","DOI":"10.15585\/mmwr.mm6707a1","volume":"67","author":"JB Croft","year":"2018","unstructured":"Croft JB, Wheaton AG, Liu Y, Xu F, Lu H, Matthews KA, et al. Urban-rural county and state differences in chronic obstructive pulmonary disease: United States, 2015. MMWR Morb Mortal Wkly Rep Wkly. 2018;67(7):205\u201311.","journal-title":"MMWR Morb Mortal Wkly Rep Wkly."},{"issue":"2","key":"1662_CR107","first-page":"229","volume":"11","author":"JA Shatto","year":"2024","unstructured":"Shatto JA, Stickland MK, Soril LJJ. Variations in COPD health care access and outcomes: a rapid review. Chronic Obstr Pulm Dis. 2024;11(2):229\u201346.","journal-title":"Chronic Obstr Pulm Dis."},{"key":"1662_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106807","volume":"197","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Wu B, Germain G, Lalibert\u00e9 F, MacKnight SD, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study. Respir Med. 2022;197:106807.","journal-title":"Respir Med"},{"issue":"5","key":"1662_CR109","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.chest.2022.09.004","volume":"162","author":"EE Cho","year":"2022","unstructured":"Cho EE, Gershon AS. Single-versus multiple inhaler triple therapy in the COPD population. Chest. 2022;162(5):947\u20138.","journal-title":"Chest"},{"issue":"1","key":"1662_CR110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41533-017-0022-1","volume":"27","author":"SL Klijn","year":"2017","unstructured":"Klijn SL, Hiligsmann M, Evers S, Rom\u00e1n-Rodr\u00edguez M, van der Molen T, van Boven JFM. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. NPJ Prim Care Respir Med. 2017;27(1):24.","journal-title":"NPJ Prim Care Respir Med."},{"issue":"1","key":"1662_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41533-025-00422-0","volume":"35","author":"M Marko","year":"2025","unstructured":"Marko M, Pawliczak R. Inhalation technique-related errors after education among asthma and COPD patients using different types of inhalers: systematic review and meta-analysis. NPJ Prim Care Respir Med. 2025;35(1):15.","journal-title":"NPJ Prim Care Respir Med."},{"key":"1662_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108251","volume":"247","author":"M Achterbosch","year":"2025","unstructured":"Achterbosch M, Hansen CME, Brand PLP, van Dijk L, van Boven JFM. Shared decision making and inhaled medication adherence in patients with COPD, asthma and cystic fibrosis: a systematic review. Respir Med. 2025;247:108251.","journal-title":"Respir Med"},{"issue":"3","key":"1662_CR113","first-page":"267","volume":"6","author":"S Cho-Reyes","year":"2019","unstructured":"Cho-Reyes S, Celli BR, Dembek C, Yeh K, Navaie M. Inhalation technique errors with metered-dose inhalers among patients with obstructive lung diseases: a systematic review and meta-analysis of U.S. studies. Chron Obstruct Pulmon Dis. 2019;6(3):267\u201380.","journal-title":"Chron Obstruct Pulmon Dis"},{"issue":"2","key":"1662_CR114","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.chest.2016.03.041","volume":"150","author":"J Sanchis","year":"2016","unstructured":"Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394\u2013406.","journal-title":"Chest"},{"issue":"6","key":"1662_CR115","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jval.2016.04.006","volume":"19","author":"AC M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher AC, Juhnke C, Beyer AR, Garner S. Patient-focused benefit-risk analysis to inform regulatory decisions: the European Union perspective. Value Health. 2016;19(6):734\u201340.","journal-title":"Value Health."},{"issue":"12","key":"1662_CR116","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jval.2020.08.2092","volume":"23","author":"JJ Carlson","year":"2020","unstructured":"Carlson JJ, Brouwer ED, Kim E, Wright P, McQueen RB. Alternative approaches to quality-adjusted life-year estimation within standard cost-effectiveness models: literature review, feasibility assessment, and impact evaluation. Value Health. 2020;23(12):1523\u201333.","journal-title":"Value Health."},{"issue":"6","key":"1662_CR117","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jval.2024.04.021","volume":"27","author":"NJ Devlin","year":"2024","unstructured":"Devlin NJ, Drummond MF, Mullins CD. Quality-adjusted life years, quality-adjusted life-year-like measures, or neither? The debate continues Value Health. 2024;27(6):689\u201391.","journal-title":"The debate continues. Value Health."},{"issue":"1","key":"1662_CR118","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jval.2019.10.014","volume":"23","author":"A Basu","year":"2020","unstructured":"Basu A, Carlson J, Veenstra D. Health years in total: a new health objective function for cost-effectiveness analysis. Value Health. 2020;23(1):96\u2013103.","journal-title":"Value Health."},{"issue":"1","key":"1662_CR119","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-016-0448-2","volume":"35","author":"S van der Schans","year":"2017","unstructured":"van der Schans S, Goossens LMA, Boland MRS, Kocks JWH, Postma MJ, van Boven JFM, et al. Systematic review and quality appraisal of cost-effectiveness analyses of pharmacologic maintenance treatment for chronic obstructive pulmonary disease: methodological considerations and recommendations. Pharmacoeconomics. 2017;35(1):43\u201363.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1662_CR120","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jval.2024.04.018","volume":"27","author":"RJ Willke","year":"2024","unstructured":"Willke RJ, Pizzi LT, Rand LZ, Neumann P. The value of the quality-adjusted life years. Value Health. 2024;27(6):702\u20135.","journal-title":"Value Health."},{"issue":"6","key":"1662_CR121","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jval.2024.03.011","volume":"27","author":"F Xie","year":"2024","unstructured":"Xie F, Zhou T, Humphries B, Neumann PJ. Do quality-adjusted life years discriminate against the elderly? An empirical analysis of published cost-effectiveness analyses. Value Health. 2024;27(6):706\u201312.","journal-title":"Value Health."},{"key":"1662_CR122","unstructured":"National Institute for Health and Care Excellence (NICE). NICE Technology Appraisal and Highly Specialised Technologies Guidance: The Manual. Manchester, UK: National Institute for Health and Care Excellence; 2026. Available from: https:\/\/www.nice.org.uk\/process\/pmg36. [Accessed 8 Jun 2026]."},{"key":"1662_CR123","unstructured":"Canada\u2019s Drug Agency (CDA-AMC). Quantitative Methods Manual. Ottawa, ON: Canada\u2019s Drug Agency; 2025. Available from: https:\/\/www.cda-amc.ca\/methods-guide. [Accessed 8 Jun 2026]."},{"issue":"2","key":"1662_CR124","first-page":"198","volume":"27","author":"LGS Bengtson","year":"2021","unstructured":"Bengtson LGS, Bancroft T, Schilling C, Buikema AR, Stanford RH. Development and validation of a drug adherence index for COPD. J Manag Care Spec Pharm. 2021;27(2):198\u2013209.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1662_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-001964","volume":"11","author":"D Vauterin","year":"2024","unstructured":"Vauterin D, Van Vaerenbergh F, Grymonprez M, Vanoverschelde A, Lahousse L. Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis. BMJ Open Respir Res. 2024;11(1):e001964.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"1662_CR126","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13561-021-00329-9","volume":"11","author":"C Guti\u00e9rrez Villegas","year":"2021","unstructured":"Guti\u00e9rrez Villegas C, Paz-Zulueta M, Herrero-Montes M, Par\u00e1s-Bravo P, Madrazo PM. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev. 2021;11(1):31.","journal-title":"Health Econ Rev."},{"key":"1662_CR127","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2147\/COPD.S163795","volume":"13","author":"JG Patel","year":"2018","unstructured":"Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis. 2018;13:2301\u201311.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1662_CR128","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40273-020-00986-4","volume":"39","author":"A Yuasa","year":"2021","unstructured":"Yuasa A, Yonemoto N, LoPresti M, Ikeda S. Use of productivity loss\/gain in cost-effectiveness analyses for drugs: a systematic review. Pharmacoeconomics. 2021;39(1):81\u201397.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1662_CR129","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232300017X","volume":"39","author":"RM Breslau","year":"2023","unstructured":"Breslau RM, Cohen JT, Diaz J, Malcolm B, Neumann PJ. A review of HTA guidelines on societal and novel value elements. Int J Technol Assess Health Care. 2023;39(1):e31.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"1662_CR130","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462324000618","volume":"40","author":"B Dawkins","year":"2024","unstructured":"Dawkins B, Shinkins B, Ensor T, Jayne D, Meads D. Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines. Int J Technol Assess Health Care. 2024;40(1):e59.","journal-title":"Int J Technol Assess Health Care"},{"key":"1662_CR131","unstructured":"Institute for Clinical and Economic Review (ICER). 2023 Value Assessment Framework. Boston, MA: Institute for Clinical and Economic Review; 2023. Updated September 25, 2023. Available from: https:\/\/icer.org\/our-approach\/methods-process\/value-assessment-framework. [Accessed 8 Jul 2026]."},{"issue":"1","key":"1662_CR132","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jval.2020.10.010","volume":"24","author":"ALV Avance\u00f1a","year":"2021","unstructured":"Avance\u00f1a ALV, Prosser LA. Examining equity effects of health interventions in cost-effectiveness analysis: a systematic review. Value Health. 2021;24(1):136\u201343.","journal-title":"Value Health."},{"issue":"5","key":"1662_CR133","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/eci.12074","volume":"43","author":"E Stamatakis","year":"2013","unstructured":"Stamatakis E, Weiler R, Ioannidis JPA. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest. 2013;43(5):469\u201375.","journal-title":"Eur J Clin Invest"},{"issue":"377","key":"1662_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069573","volume":"22","author":"F Xie","year":"2022","unstructured":"Xie F, Zhou T. Industry sponsorship bias in cost effectiveness analysis: registry based analysis. BMJ. 2022;22(377):e069573.","journal-title":"BMJ"},{"issue":"1","key":"1662_CR135","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s41669-020-00235-6","volume":"5","author":"A Yuasa","year":"2021","unstructured":"Yuasa A, Yonemoto N, Demiya S, Foellscher C, Ikeda S. Investigation of factors considered by health technology assessment agencies in eight countries. Pharmacoecon Open. 2021;5(1):57\u201369.","journal-title":"Pharmacoecon Open."},{"issue":"6","key":"1662_CR136","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force--3. Value Health. 2012;15(6):812\u201320.","journal-title":"Value Health"},{"issue":"1","key":"1662_CR137","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2014.12.001","volume":"18","author":"DA Marshall","year":"2015","unstructured":"Marshall DA, Burgos-Liz L, IJzerman MJ, Osgood ND, Padula WV, Higashi MK, et al. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force. Value Health. 2015;18(1):5\u201316.","journal-title":"Value Health"},{"issue":"3","key":"1662_CR138","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jval.2018.10.008","volume":"22","author":"M Hoogendoorn","year":"2019","unstructured":"Hoogendoorn M, Corro Ramos I, Baldwin M, Gonzalez-Rojas Guix N, Rutten-van M\u00f6lken MPMH. Broadening the perspective of cost-effectiveness modeling in chronic obstructive pulmonary disease: a new patient-level simulation model suitable to evaluate stratified medicine. Value Health. 2019;22(3):313\u201321.","journal-title":"Value Health."},{"issue":"3","key":"1662_CR139","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1513\/pats.200507-072SF","volume":"3","author":"DM Halpin","year":"2006","unstructured":"Halpin DM. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(3):227\u201333.","journal-title":"Proc Am Thorac Soc"},{"issue":"4","key":"1662_CR140","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40271-014-0064-1","volume":"7","author":"AK Kawata","year":"2014","unstructured":"Kawata AK, Kleinman L, Harding G, Ramachandran S. Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD). Patient. 2014;7(4):413\u201326.","journal-title":"Patient"},{"issue":"6","key":"1662_CR141","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1524-4733.2007.00205.x","volume":"10","author":"D Hughes","year":"2007","unstructured":"Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health. 2007;10(6):498\u2013509.","journal-title":"Value Health."},{"issue":"1","key":"1662_CR142","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jval.2015.07.009","volume":"19","author":"SL Brilleman","year":"2016","unstructured":"Brilleman SL, Metcalfe C, Peters TJ, Hollingworth W. The reporting of treatment nonadherence and its associated impact on economic evaluations conducted alongside randomized trials: a systematic review. Value Health. 2016;19(1):99\u2013108.","journal-title":"Value Health."},{"issue":"10","key":"1662_CR143","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jval.2021.04.1284","volume":"24","author":"SD Reed","year":"2021","unstructured":"Reed SD, Yang JC, Gonzalez JM, Johnson FR. Quantifying value of hope. Value Health. 2021;24(10):1511\u20139.","journal-title":"Value Health."},{"issue":"1","key":"1662_CR144","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0272989X15583266","volume":"36","author":"M Asaria","year":"2016","unstructured":"Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a tutorial. Med Decis Making. 2016;36(1):8\u201319.","journal-title":"Med Decis Making"},{"issue":"4","key":"1662_CR145","first-page":"400","volume":"26","author":"LP Garrison","year":"2020","unstructured":"Garrison LP, Zamora B, Li M, Towse A. Augmenting cost-effectiveness analysis for uncertainty: the implications for value assessment: rationale and empirical support. J Manag Care Spec Pharm. 2020;26(4):400\u20136.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"1662_CR146","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jval.2024.04.013","volume":"27","author":"WV Padula","year":"2024","unstructured":"Padula WV, Kolchinsky P. Can eneralized cost-effectiveness analysis leverage meaningful use of novel value elements in pharmacoeconomics to inform Medicare drug price negotiation? Value Health. 2024;27(8):1100\u20137.","journal-title":"Value Health."},{"issue":"11","key":"1662_CR147","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jval.2019.06.014","volume":"22","author":"R Baltussen","year":"2019","unstructured":"Baltussen R, Marsh K, Thokala P, Diaby V, Castro H, Cleemput I, et al. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward. Value Health. 2019;22(11):1283\u20138.","journal-title":"Value Health."},{"issue":"1","key":"1662_CR148","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jval.2016.08.724","volume":"20","author":"K Marsh","year":"2017","unstructured":"Marsh K, Zaiser E, Orfanos P, Salverda S, Wilcox T, Sun S, et al. Evaluation of COPD treatments: a multicriteria decision analysis of aclidinium and tiotropium in the United States. Value Health. 2017;20(1):132\u201340.","journal-title":"Value Health."},{"issue":"2","key":"1662_CR149","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40273-025-01561-5","volume":"44","author":"S Harvard","year":"2026","unstructured":"Harvard S, Carter R, Cheong SH, Lanier T, Zeyan Z, Adibi A, et al. The \u2018values in modelling\u2019 framework for patient and public involvement in health economics modelling: development and application in the LEAP model project. Pharmacoeconomics. 2026;44(2):115\u201339.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1662_CR150","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jval.2016.11.014","volume":"20","author":"EM Perfetto","year":"2017","unstructured":"Perfetto EM, Oehrlein EM, Boutin M, Reid S, Gascho E. Value to whom? The patient voice in the value discussion. Value Health. 2017;20(2):286\u201391.","journal-title":"Value Health."},{"key":"1662_CR151","unstructured":"Pearson S. ICER\u2019s new patient engagement program: amplifying the patient voice before, during, and after a value assessment. 2026. Available from: https:\/\/icer.org\/news-insights\/commentaries\/icers-new-patient-engagement-program-amplifying-the-patient-voice-before-during-and-after-a-value-assessment\/. [Accessed 26 Aug 2026]."},{"issue":"1","key":"1662_CR152","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40900-023-00444-3","volume":"9","author":"S Staniszewska","year":"2023","unstructured":"Staniszewska S, Jakab I, Low E, Mossman J, Posner P, Husereau D, et al. Commentary: advocating for patient and public involvement and engagement in health economic evaluation. Res Involv Engagem. 2023;9(1):45.","journal-title":"Res Involv Engagem."},{"issue":"5","key":"1662_CR153","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40271-020-00433-8","volume":"13","author":"S dosReis","year":"2020","unstructured":"dosReis S, Butler B, Caicedo J, Kennedy A, Hong YD, Zhang C, et al. Stakeholder-engaged derivation of patient-informed value elements. Patient. 2020;13(5):611\u201321.","journal-title":"Patient"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01662-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:02:20Z","timestamp":1792720940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":153,"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01662-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Julia F. Slejko reports unrelated funding from AstraZeneca and Genentech, Inc. and consulting for Boehringer Ingelheim, Merck, and Teva Pharmaceuticals for work unrelated to the research presented in this paper. Nabin Poudel, Lodise Leah, Jiwon Oh, Victoria Lee, and Salome Ricci have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used in this article are available in the public domain in the sources referenced.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by NP, LL, VL, and SR. The first draft of the manuscript was written by NP, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}